NCT02390063View on ClinicalTrials.gov

Vaccination in Prostate Cancer (VANCE)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

May 15, 2018

Study Completion Date

May 15, 2019

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

ChAdOx1.5T4

A recombinant simian adenovirus encoding human tumour-associated antigen 5T4

BIOLOGICAL

MVA.5T4

A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4

DRUG

Cyclophosphamide

Metronomic cyclophosphamide (50mg bd)

Trial Locations (2)

OX3 7DQ

University of Oxford, Oxford

S10 2IF

Royal Hallamshire Hospital, Sheffield

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02390063 - Vaccination in Prostate Cancer (VANCE) | Biotech Hunter | Biotech Hunter